Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Cellectar Biosciences announced positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in 55 patients with...
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals has dosed the first patient in its Phase 3 ASPENOVA clinical trial (NCT07546500) evaluating azenosertib for Cyclin E1-positive...
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma reported its first-quarter 2026 financial results and provided an update on its NXP900 clinical program. The company is actively enrolling...
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in
Sarepta Therapeutics is navigating significant challenges, including patient deaths linked to its gene therapy Elevidys, but is poised for several key...
Viridian Data Lift Prospects for Thyroid Eye Disease Drug
Viridian Therapeutics announced positive late-stage data for its subcutaneous drug, elegrobart, in patients with chronic thyroid eye disease. The trial...
QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS
QurAlis presented interim Phase 2 data for its antisense oligonucleotide (ASO), QRL-201, in 69 patients with amyotrophic lateral sclerosis (ALS) at Target...
Clinical Trial Updates07 May 2026
Cellectar Biosciences announced positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in 55 patients with...
Clinical Trial Updates07 May 2026
Zentalis Pharmaceuticals has dosed the first patient in its Phase 3 ASPENOVA clinical trial (NCT07546500) evaluating azenosertib for Cyclin E1-positive...
Clinical Trial Updates07 May 2026
Nuvectis Pharma reported its first-quarter 2026 financial results and provided an update on its NXP900 clinical program. The company is actively enrolling...
Clinical Trial Updates07 May 2026
Sarepta Therapeutics is navigating significant challenges, including patient deaths linked to its gene therapy Elevidys, but is poised for several key...
Clinical Trial Updates07 May 2026
Viridian Therapeutics announced positive late-stage data for its subcutaneous drug, elegrobart, in patients with chronic thyroid eye disease. The trial...
Clinical Trial Updates07 May 2026
QurAlis presented interim Phase 2 data for its antisense oligonucleotide (ASO), QRL-201, in 69 patients with amyotrophic lateral sclerosis (ALS) at Target...
Regulatory Approvals07 May 2026
A single case of hepatic failure associated with Eli Lilly’s weight-loss pill Foundayo was reported in the FDA’s Adverse Event Reporting System (FAERS),...
Regulatory Approvals05 May 2026
Passage Bio is cutting approximately 75% of its workforce, impacting around 18 employees, to reduce operating expenses. This decision follows the FDA's...
Regulatory Approvals05 May 2026
Argenx is seeking to expand the label of its generalized myasthenia gravis (gMG) drug, Vyvgart, to include patients who are seronegative for acetylcholine...
Regulatory Approvals05 May 2026
The FDA has approved Veppanu (vepdegestrant), developed by Pfizer and Arvinas, as the first-ever PROTAC therapy for advanced or metastatic ER-positive,...
Regulatory Approvals05 May 2026
The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against the approval of AstraZeneca's oral SERD camizestrant for HER2-negative advanced breast...
Regulatory Approvals01 May 2026
UniQure announced plans to submit a marketing application for its gene therapy, AMT-130, in the U.K. later this year, following a positive meeting with U.K....
Mergers and Acquisitions08 May 2026
Bayer has ended a nearly five-year M&A hiatus in its pharma division by acquiring Perfuse Therapeutics for an upfront payment of $300 million, with the total...
Mergers and Acquisitions07 May 2026
Pfizer reported Q1 2026 revenue of $14.5 billion, a 2% increase, and maintained its full-year guidance. The company's long-term strategy focuses on achieving...
Mergers and Acquisitions07 May 2026
Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage small...
Mergers and Acquisitions05 May 2026
UCB is set to acquire immunology specialist Candid Therapeutics in a deal valued at up to $2.2 billion, comprising $2 billion upfront and up to $200 million in...
Mergers and Acquisitions01 May 2026
AstraZeneca is reshaping its pipeline, discontinuing four assets including atuliflapon, an oral FLAP protein inhibitor for moderate to severe asthma, due to...
Mergers and Acquisitions30 Apr 2026
Teva Pharmaceutical has announced the acquisition of privately held Emalex Biosciences for up to $900 million, comprising $700 million upfront and up to $200...
Pharma competitive intelligence04 May 2026
Explains how pharma teams are shifting from quarterly reports to real-time signals for competitive intelligence, improving visibility and faster decision-making.
04 May 2026
Explains how clinical trial intelligence is reducing manual landscape analysis in drug development, improving speed, consistency, and planning decisions.
AI authoring platform04 May 2026
Explains how AI authoring platforms help create living, traceable regulatory submissions in life sciences, supporting consistency, updates, and compliance.
enterprise AI platform29 Apr 2026
An enterprise AI platform enables organizations to build, deploy, and manage AI solutions at scale. Learn how to evaluate trusted, explainable AI systems that meet compliance and transparency requirements in regulated industries.
KnolPersona31 Mar 2026
The EU Joint Clinical Assessment (JCA) regulation became mandatory for these product classes, creating a single EU-level clinical assessment that runs in parallel with the EMA regulatory review, not after it. For pharma teams accustomed to beginning HTA dossier preparation following regulatory approval, this is a strategic and operational discontinuity of the first order.
competitive intelligence29 Mar 2026
In the pharmaceutical industry, where a single competitor's Phase III readout can reshape a multi-billion dollar market overnight, the difference between knowing first and knowing last is not a matter of competitive preference. It is a matter of commercial survival.
Private by design. Speaks your language. Proven at scale
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
